Race Oncology: Secures human ethics trial approval

Race Oncology Secures human ethics trial approval

  • Race Oncology (RAC) receives human ethics approval for the next stage of its clinical trial of Zantrene in breast cancer patients
  • The company received the approval from the Hunter New England Human Research Ethics Committee for the observational stage of a planned phase 1/2b cardioprotection clinical program using Zantrene
  • The company must now submit and receive research institutional governance approval before patients can be enrolled and treated in the study
  • Race says the human trials will be fully funded from its December 2021 capital raise
  • RaceOncology is up 3.99 per cent, trading at $1.96 at 2:51 pm AEDT
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

SMBC Winds Down Digital US Bank Jenius, Impacting Customers

The closure illustrates the challenges facing digital banks in the US.Highlights: SMBC announces the closure of its US...

Scammers Impersonate NAB Trade’s Tom Piotrowski to Endorse Fraudulent Investments

NAB Trade warns investors about the ongoing impersonation scams targeting clients.Highlights: Scammers are impersonating Tom Piotrowski from NAB...

Bermuda Strengthens Onchain Economy with New Regulatory Framework

Government seeks to attract blockchain innovation and investment.Highlights: Bermuda introduces new regulations to boost its onchain economy.The framework...

Australia Tightens Cash Acceptance Rules for Retailers

New regulations will impact how retailers handle cash transactions.Highlights: Australia introduces stricter cash acceptance rules for retailers.The new...